Immunotherapy trials on cancer presented to leaders of key opinion -
Immodulon recently met some of the most renowned oncologists in the world to present their upcoming trials for treatment immunotherapy, IMM-101. Their comments were extremely positive and allows Immodulon to go ahead with planning a pivotal trial for the launch next year, and additional exploratory surveys IMM-101 in combination with other treatments for begin later this year.
IMM-101 is a natural medical treatment that helps the body's immune system to recognize and fight against cancer. It works in combination with other anti-cancer treatments to improve the overall outcome for the patient, and does not correspond to toxicity levels in the body. Clinical studies indicate that IMM-101 has a potentially transformational impact on survival rates for cancer.
Immodulon presented the following experts at ESMO in Barcelona, who all indicated they support the testing and Immodulon to work in research of immunotherapy
- Professor David Cunningham, Royal Marsden Hospital, London
- Professor Michel Ducreux, Institut Gustave Roussy, Paris
- Professor Jean-Yves Blay, Claude Bernard University, Lyon
- Professor Eileen O O'Reilly, Memorial Sloan Kettering Cancer Center, New York
- Professor Margaret Tempero, University of California, San Francisco
- Dr Harpreet Wasan, Hammersmith Hospital, Imperial College London
- Hospitals, London Dr Andrew Gaya, Guy and St Thomas
- Dr Aurelien Marabelle, Institut Gustave Roussy, Paris
- Dr Anna-Mary Young, St George's hospital, London
- Dr. Noreen Starling, Royal Marsden Hospital, London
Professor David Cunningham, Consultant medical oncologist at the Royal Marsden said, "Immodulon is breaking new ground in the treatment of cancer immunotherapy. I am very pleased to have accepted the role of the lead investigator in their next test in this exciting new field. "
Immodulon President Charles Akle said." We are extremely proud to have had such positive feedback on our study designs of some of the brightest minds in oncology Immodulon use this approval to move to Phase III trials and make IMM-101 on the market in the most efficient and affordable manner. "
EmoticonEmoticon